• Neovascular (wet) age-related macular degeneration (AMD):
    • 5mg intravitreal once monthly
    • May decrease to 0.5mg every 2 months after 3 doses OR 0.5mg every 3 months after 4 doses
      • Less frequent dosing not as effective as monthly dosing
  • Diabetic retinopathy in patients with or without diabetic macular edema (DME)
    • 3 mg intravitreal once monthly
  • Macular edema following retinal vein occlusion
    • 5mg intravitreal once monthly *6/12
  • Myopic choroidal neovascularization (mCNV):
    • 5mg intravitreal once monthly up to 3 months
    • May repeat treatment based on response

Injection: 10mg/mL

  • Prior to and 30 minutes following intravitreal injection, monitor for elevation in intraocular pressure

VEGF Inhibitors

It binds and inhibits vascular endothelial growth factor A, decreasing neovascularization, vascular permeability and endothelial cell proliferation

  • Conjunctival hemorrhage
  • Ocular pain
  • Vitreous floaters
  • Increased IOP
  • Foreign body sensation
  • Blurred vision
  • Ocular discomfort
  • Ocular irritation
  • Ocular inflammation
  • Ocular hyperemia
  • Increased lacrimation
  • Dry eyes
  • Blepharitis
  • Retinal disorder
  • Posterior capsule opacification
  • Hypersensitivity
  • Ocular/periocular infections

None restricted

                                   Drug Status

Availability Prescription only
Pregnancy Weigh risk vs benefit
Breastfeeding Use with caution
Schedule Not controlled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Lucentis 10mg/mL Injection 1’s Novartis Pharma Novartis Kenya